• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Introduction to trans-stilbene-alpha,alpha'-d2 (CAS No. 5284-44-6)

The compound trans-stilbene-alpha,alpha'-d2, with the chemical identifier CAS No. 5284-44-6, is a deuterated derivative of trans-stilbene, a naturally occurring stilbenoid found in various plants. Stilbenes are known for their diverse biological activities, and the deuterated version, trans-stilbene-alpha,alpha'-d2, has garnered significant interest in the field of chemical biology and pharmaceutical research due to its unique properties and potential applications.

In recent years, the study of deuterated compounds has seen a surge in popularity, particularly in the development of drug candidates that exhibit improved metabolic stability and reduced toxicity. The introduction of deuterium atoms into molecular structures can alter the pharmacokinetic properties of a compound, often leading to enhanced bioavailability and prolonged half-life. This has made deuterated stilbenes, such as trans-stilbene-alpha,alpha'-d2, attractive candidates for further investigation in medicinal chemistry.

The chemical structure of trans-stilbene-alpha,alpha'-d2 consists of two phenyl rings connected by an ethylene bridge, with deuterium atoms substituting at the alpha positions of the ethylene group. This modification not only imparts unique spectroscopic properties but also influences its interactions with biological targets. The compound's ability to modulate various signaling pathways has been a focal point of research, particularly in the context of anti-cancer and anti-inflammatory applications.

One of the most compelling aspects of trans-stilbene-alpha,alpha'-d2 is its potential as an anti-cancer agent. Stilbenes, including trans-stilbene itself, have been shown to exhibit chemopreventive and chemotherapeutic effects by inhibiting key enzymes involved in cell proliferation and survival. The deuterated derivative, trans-stilbene-alpha.alpha'-d2, has been investigated for its ability to disrupt cancer cell signaling pathways such as PI3K/Akt and MAPK. Preclinical studies have demonstrated that trans-stilbene-alpha.alpha'-d2 can induce apoptosis in various cancer cell lines while maintaining low toxicity towards normal cells.

In addition to its anti-cancer properties, trans-stilbene-alpha.alpha'-d2 has shown promise in the treatment of inflammation-related diseases. Chronic inflammation is a hallmark of many pathological conditions, including arthritis and cardiovascular diseases. Research indicates that stilbenes can modulate inflammatory responses by inhibiting nuclear factor kappa B (NF-κB) signaling. The deuterated version, trans-stilbene-alpha.alpha'-d2, has been found to exhibit similar anti-inflammatory effects while potentially offering improved pharmacokinetic profiles.

The pharmacological activity of trans-stilbene-alpha.alpha'-d2 is further enhanced by its ability to cross the blood-brain barrier, making it a potential candidate for treating neurodegenerative disorders. Studies have suggested that stilbenes can protect against oxidative stress and inflammation in neural cells, which are key factors in conditions such as Alzheimer's disease and Parkinson's disease. The deuterated derivative, trans-stilbene-alpha.alpha'-d2, may offer a more stable and effective therapeutic option for these conditions due to its improved metabolic profile.

The synthesis of trans-stilbene-alpha.alpha'-d2 involves sophisticated organic chemistry techniques, including cross-coupling reactions and deuteriumation methods. Advanced synthetic methodologies have enabled researchers to produce high-purity samples of this compound, facilitating detailed structural elucidation and biological testing. The development of efficient synthetic routes has been crucial for scaling up production, which is essential for both preclinical and clinical studies.

The analytical characterization of trans-stilbene-alpha.alpha'-d2 relies on state-of-the-art spectroscopic techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). These techniques provide detailed information about the molecular structure and purity of the compound, ensuring that it meets the stringent requirements for pharmaceutical applications. Additionally, computational methods such as molecular dynamics simulations have been employed to predict the interactions between trans-stilbene-alpha.alpha'-d2 and biological targets, aiding in the design of more effective derivatives.

In conclusion, trans-stilbene-alpha.alpha'-d2, with the CAS number 5284-44-6, represents a promising area of research in chemical biology and pharmaceutical development. Its unique structural features and biological activities make it a valuable tool for investigating novel therapeutic strategies against cancer, inflammation, and neurodegenerative diseases. As research continues to uncover new applications for this compound, it is likely that trans-stilbene-alpha.alpha'-d2 will play an increasingly important role in future medical treatments.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)